Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?

J Hypertens. 2024 Mar 1;42(3):396-398. doi: 10.1097/HJH.0000000000003643. Epub 2024 Feb 1.

Authors

Bi Huang¹, Garry McDowell^{1

2}, Anirudh Rao^{1

3}, Gregory Y H Lip^{1

4}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
² School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University.
³ Department of Nephrology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
⁴ Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

PMID: 38289999
DOI: 10.1097/HJH.0000000000003643

No abstract available

MeSH terms

Acute Kidney Injury*
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use
Receptors, Mineralocorticoid
Renal Insufficiency, Chronic* / drug therapy

Substances

Mineralocorticoid Receptor Antagonists
Receptors, Mineralocorticoid

Associated data

ClinicalTrials.gov/NCT03020303